Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

atient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor:

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media:

Andrea tenBroek

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com


'/>"/>
SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and NOTTINGHAM, England , July ... CBRX ) today announced that its ... announced a collaboration that will support pharmaceutical and ... development stage.  Molecular Profiles, pharmaceutical development services will ... metabolism and pharmacokinetics (DMPK) to give clients a ...
(Date:7/31/2014)... July 31, 2014  Today,s Consumer Reports story ... an important reminder for consumers of the importance ... of initiatives such as the Acetaminophen Awareness Coalition,s ... consumer education campaign. Formed in 2010, the Coalition ... and consumer organizations dedicated to educating consumers on ...
(Date:7/30/2014)... 30, 2014 Advanced Photonix ® (NYSE MKT: ... 2014) financial results on Monday, August 11, 2014. A press ... close of the market and the Company will host a ... p.m. EDT on the same day. Participating in ... Director), Rob Risser (COO and Director), and ...
Breaking Medicine Technology:Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis 2Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis 3U.S. Health Coalition Calls for Continued Education on Acetaminophen, America's Most Common Drug Ingredient 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2
... VIENNA, Va., Sept. 17 CEL-SCI Corporation,(AMEX: ... Executive Officer, Geert Kersten, is a,featured presenter ... is scheduled for Tuesday, September 18, 2007 ... be accessed via the Internet at,CEL-SCI,s website ...
... 17 In a new analysis reported,at the ... 29th Annual,Meeting, risedronate 5 mg decreased clinical fracture ... in a group of postmenopausal women with,osteoporosis who ... of the risedronate HIP trial(1) evaluated the combined ...
Cached Medicine Technology:CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 3Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 4
(Date:7/31/2014)... India (PRWEB) July 31, 2014 RankingBySEO, ... service for those individuals and organizations against whom negative ... as ‘Remove Negative Comments Service’. , About the ... “We have officially announced the service now, but we ... rid of negative comments for several years.” , On ...
(Date:7/31/2014)... 31, 2014 T.E.N., a technology ... honored finalists and winners Wednesday evening, July 30, ... Awards Gala at the Westin St. Francis in ... information security for the BlackLine Systems, was selected ... Award winner for the ISE® West Region. As ...
(Date:7/31/2014)... Steven Reinberg HealthDay Reporter ... regulation of electronic cigarettes isn,t warranted based on current ... contrary, allowing e-cigarettes to compete with regular cigarettes might ... reviewing 81 prior studies on the use and safety ... suggests that there is a potential for smokers to ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 ... Marketing Company, has introduced a new service named ... , Ethane Web Technologies has designed the service ... of clients and Java Development service being provided ... the company a confidence to promise outstanding Java ...
(Date:7/31/2014)... 2014 Bedros Keuilian’s Fit Body Boot Camp ... other countries. At his annual Fitness Business Summits, some of ... their marketing strategies. But in his latest blog post, he ... marketing a personal training business is to create free ... personal trainer has a certain area that they really feel ...
Breaking Medicine News(10 mins):Health News:RankingBySEO Launches a New Service ‘Remove Negative Comments’ 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 3
... difference in effectiveness of 5 drugs currently available , , ... that any one of the five drugs available in ... the others, says an American College of Physicians (ACP) ... just issued a new guideline on drug treatment of ...
... Publishing, an award-winning interactive, visual content developer, today ... the first free, Web-based 3-D interactive model of ... educators, and health and medical professionals, The Visible ... how the human body works. It will also ...
... ANNAPOLIS, Md., March 4 Dozens of ... gathered in Annapolis today as,the General Assembly ... regulations, protections against identity theft, and the ... visited legislators,offices and attended committee hearings on ...
... Market Segments, CHICAGO, March 4 Throw ... Financial services firms, insurers, and,healthcare payors admit they ... to serve baby boomers, who will control some ... who make up the wealthiest generation in history, ...
... CA A nuclear receptor protein, known for controlling ... powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice ... research by scientists at the Salk Institute for Biological ... , Their findings, reported in this weeks online edition ...
... swayed by adolescent drug use trends , , TUESDAY, March 4 ... boys are more likely to give up the habit if ... no matter what, new research shows. , The findings ... to the wider world,s embrace of illegal drugs, said study ...
Cached Medicine News:Health News:Groups Issue New Dementia Drug Guidelines 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Utilities, Long Term Care Bills at Center of 'AARP Day In Annapolis' 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 3Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 4Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 5Health News:New potential drug target for the treatment of atherosclerosis 2Health News:New potential drug target for the treatment of atherosclerosis 3Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2
... for the Anterior Segment The BD is ... and ophthalmologists specializing in the anterior segment. It ... Video- c-mount camera on the BD 900- may ... magnification in 10 and 16 X times- through ...
... new functional test which exhibits 100% sensitivity ... Resistance caused by the Factor V Leiden ... available methods, Pefakit APC-R FVL shows no ... Anticoagulants, Elevated FVIII levels, Heparins or Prothrombin ...
... for venous pressure monitoring, blood sampling, ... Turbo-Flo polyurethane PICC line sets offer:, ... Micropuncture Introducer Needle, Biocompatible ... trimmed to patient specific anatomy. Remove ...
Assess serum Gc-globulin levels in patients with multiple trauma, fulminant liver failure, acetaminophen overdose, and sepsis....
Medicine Products: